A novel therapeutic option for castration-resistant prostate cancer: after or before chemotherapy?

Eur Urol. 2014 May;65(5):905-6. doi: 10.1016/j.eururo.2013.06.034. Epub 2013 Jun 25.

Authors

Alessandro Sciarra¹, Stefano Salciccia²

Affiliations

¹ Prostate Cancer Unit, Department of Urology, University Sapienza, Policlinico Umberto I, Rome, Italy. Electronic address: sciarra.md@libero.it.
² Department of Urology, University Sapienza, Rome, Italy.

PMID: 23838638
DOI: 10.1016/j.eururo.2013.06.034

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents / adverse effects*
Bone Neoplasms / drug therapy*
Humans
Male
Prostatic Neoplasms, Castration-Resistant / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Abituzumab